The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Open accessAbstract
PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“consistent differences in outcomes (OS and IDFS) have emerged across phase III studies of these therapies”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [22]
In the citing paper
“which in contrast to abemaciclib and ribociclib, has not shown a clinically meaningful or statistically significant difference in OS in the firstor second-line ABC setting or an invasive disease-free survival (IDFS) benefit in the EBC setting.17,18,21,22”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [22]
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationHarbeck, N., & Gnant, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,387
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martín, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,056
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–235 of 235
Systemic Therapy for Breast Cancer
Hallmeyer, S., Qamar, R., & Shamah, C. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93249-3.00009-6
Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung
Krawczyk, N., Fehm, T. N., Stickeler, E., Thomssen, C., Thill, M., Fick, F., Rody, A., & Banys‐Paluchowski, M. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05219-9
A review of endocrine therapy for hormone-dependent breast cancer
Наримановна, У. А., Kaliberdenko, V. B., Maryanenko, S. P., Al-Nsour, J. M., & Korenkova, A. A. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-3-159-167
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4
Targeting CDK4 and CDK6 in hormone-dependent cancers
Bobbitt, J. R., & Keri, R. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.006
Was ist neu in der systemischen Behandlung des frühen Mammakarzinoms?
Trapp, E. K. (2024) · Gynäkologie in der Praxis · doi:10.1007/s41974-024-00340-y · Cited by 1
Dual Inhibitors of CDK4 /6 for Treating Cancer
Toogood, P. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch22
Oncological Treatment of Breast Cancer
Açar, F. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-75480-7_3
Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach
Andrahennadi, S., & Manna, M. (2025) · Canadian oncology today. · doi:10.58931/cot.2025.2134
Saint‐Ghislain, M., Chabaud, S., Dalenc, F., Allouache, D., Cameron, D., Martinez, M., Grenier, J., Barthélémy, P., Brunt, M., Kaluzinski, L., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105050
Self-citationHormonothérapie en situation adjuvante en fonction du risque
Cabal, J., Lescure, C., Dieras, V. C., & Du, F. L. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.06.003
Liu, Y., Su, J., Wu, P., & Lv, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1564437
Zhuo, Q., Wang, K., Jia, X., Wang, X., & Li, M. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004113
Sanò, M. V., Marino, L., Puleo, M., Pafumi, S., Marletta, S., Ricciardi, G. R. R., & Carnaghi, C. (2025) · Diagnostics · doi:10.3390/diagnostics15233042
Xu, R. Y., Kato, D., Percival, V., Schoales, J., Sundquist, S., Chowdhury, R., Pond, G. R., & Dancey, J. E. (2025) · Cancers · doi:10.3390/cancers17244009
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petráková, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070298
Matrenin, К. I., Teptsova, T. S., Slabikova, A. A., Ильвисович, З. С., Krekhtunova, L. O., Валерьевич, С. И., & Kolyadina, I. V. (2025) · Medical Technologies Assessment and Choice · doi:10.17116/medtech20254704164
Golemba, A. S., Mandó, P., Bolaño, A. L. J., Torres, S. P. R., Moranth, R. V., & Santamaría, A. A. A. (2026) · Cureus · doi:10.7759/cureus.101836
Lee, E.-S., Calindas-Mendoza, M. R., Jung, S. P., Moon, H., & Han, W. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111419
Zhou, J., Guo, H., Wan, M., Xue, N., Yan, T., Zhu, Y., Hu, F., & Zhang, A. (2026) · Natural Product Communications · doi:10.1177/1934578x261418401
Neue endokrine Therapiekonzepte beim Mammakarzinom
Gschwantler-Kaulich, D. (2026) · Gynäkologie in der Praxis · doi:10.1007/s41974-026-00407-y
Adjuvant endocrine therapy in high-risk HR-positive and HER2-negative early breast cancer
Reverdy, T., Nannini, S., Freyer, G., & Corbaux, P. (2026) · Academia oncology. · doi:10.20935/acadonco8139
The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer
Ohm, H., Lohrisch, C. A., LeVasseur, N., Simmons, C., & Mitri, Z. I. (2026) · Cancers · doi:10.3390/cancers18071130
Khalkho, V. M., Yadav, S. K., Mandwe, M., ., D., Pavunraj, M., & Dave, A. (2026) · Cureus · doi:10.7759/cureus.106930
Valencia, G., Morante, Z., Ferreyra, Y., Jacome, R., Rioja, P., Saavedra, A., Neciosup, S. P., Vidaurre, T., & Gómez, H. (2026) · Biomedicines · doi:10.3390/biomedicines14040893
Pernas, S., Forns, X., Martínez-Sáez, O., Andrade, R. J., Amador, A., López-Miranda, E., Bermejo, B., Mateos, B., Solís, M. C., Villanueva, M. J., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04369-7
Self-citationChang, Y.-H., Chen, Y., Hong, Z.-J., Hsiao, Y., Lin, K., Liao, G.-S., Sheng-Fang, S., Lin, Z., Chen, H.-W., Han, C., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02701-x
Cottu, P. H., Pascual, T., Lemonnier, J., Hu, H., Roux, E., Connolly, R. M., Ma, C. X., Wolff, A. C., Crestani, T., Tolosa, P., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261467380
Self-citationNeoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS
Battina, R., Mainor, C. B., Schmidt, M. O., Gallanis, G. T., Sharif, G. M., Walsh, E., Whitaker, K. D., Greenwalt, I., Cruz, L. D. L., Swanson, N., et al. (2026) · Cancers · doi:10.3390/cancers18162630
The repurposing era of CDK4/6 in the treatment of various ailments
Joshi, R., Soni, D., Kaur, C. D., Ravi, N. K., Singh, P. K., & Gupta, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44611-5.00001-8
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer
Smith, C. E. P., Sammons, S. L., Minami, C. A., Sedrak, M. S., Magnuson, A. M., O’Connor, T., Hshieh, T. T., Smith, S., Ruderman, K. R., Bak, K., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.3121
Metabolic Outcome and CV Risk in Breast Cancer Patients
Felicetti, F., Mittica, G., Cavallin, C., Campus, E., Salerno, E., Gatti, F., Beano, A., Ricardi, U., Arvat, E., & Fortunati, N. (2026) · Endocrines · doi:10.3390/endocrines7030050
The role of CDK4/6 inhibitors in the treatment of luminal HER2/neu-negative early breast cancer
Potselueva, P. D., Физулиевна, Е. С., & Kornietskaya, A. L. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-258
Real-World Effectiveness, Safety, and Tolerability of Adjuvant CDK4/6 Inhibitor Therapy
Shah, K., Panchal, H. P., Patel, A., & Yadav, R. (2026) · Cureus · doi:10.7759/cureus.117479
Sjöberg, J., Smith, D. R., Ekstrand, J., Hinnen, P., Cikman, I., Valachis, A., & Lundgren, C. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.104639
Metadata
- Authors
- Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., Pfeiler, G., Miller, K. D., Colleoni, M., Suga, J. M., Rubovsky, G., Bliss, J. M., Mayer, I. A., Singer, C. F., Nowecki, Z., Hahn, O., Thomson, J., Wolmark, N., Amillano, K., Rugo, H. S., Steger, G. G., Hernando Fernández de Aránguiz, B., Haddad, T. C., Perelló, A., Bellet, M., Fohler, H., Metzger Filho, O., Jallitsch-Halper, A., Solomon, K., Schurmans, C., Theall, K. P., Lu, D. R., Tenner, K., Fesl, C., DeMichele, A., Mayer, E. L., & on behalf of the PALLAS groups and investigators
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- Mayo Clinic (US)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Dana-Farber Cancer Institute (US)
- Paracelsus Medical University (AT)
- Government of New South Wales (AU)
- Johns Hopkins University (US)
- Curtin University (AU)
- Indiana University Health (US)
- European Institute of Oncology (IT)
- Kaiser Permanente Vallejo Medical Center (US)
- National Institute of Oncology, Budapest, Hungary
- Institute of Cancer Research (GB)
- Vanderbilt University Medical Center (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University of Chicago (US)
- Peninsula Health (AU)
- University of Pittsburgh (US)
- Hospital Universitari Sant Joan de Reus (ES)
- University of California, San Francisco (US)
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
- Hospital Universitario Son Espases (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Alliance Foundation Trials (US)
- BIG, Brussels, Belgium
- Pfizer (United States) (US)
- University of Pennsylvania (US)
- GEICAM – Spanish Breast Cancer Group (ES)
- ORCID
- Gnant, Michael
- Dueck, Amylou C.
- Martin, Miguel
- Greil, Richard
- Fox, Peter
- Wolff, Antonio C.
- Chan, Arlene
- Winer, Eric P.
- Pfeiler, Georg
- Miller, Kathy D.
- Colleoni, Marco
- Suga, Jennifer M.
- Rubovsky, Gabor
- Bliss, Judith M.
- Mayer, Ingrid A.
- Singer, Christian F.
- Nowecki, Zbigniew
- Thomson, Jacqui
- Wolmark, Norman
- Amillano, Kepa
- Rugo, Hope S.
- Steger, Guenther G.
- Hernando Fernández de Aránguiz, Blanca
- Haddad, Tufia C.
- Perelló, Antonia
- Bellet, Meritxell
- Metzger Filho, Otto
- Schurmans, Céline
- Lu, Dongrui R.
- Tenner, Kathleen
- Fesl, Christian
- DeMichele, Angela
- Mayer, Erica L.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-01-20
- Volume
- 40
- Issue
- 3
- Pages
- 282-293
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10476784
- OpenAlex
- W4200066800
- Cited by
- 235
- References
- 46
- Citations by year
- 2026: 26 · 2025: 70 · 2024: 56 · 2023: 51 · 2022: 32
- FWCI
- 22.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Pfizer
- Cancer Research UK (25351)
- National Institute for Health and Care Research (NIHR202432)
- National Cancer Institute (U10CA180868, R01CA214893)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, early breast cancer, hormone receptor-positive breast cancer, HER2-negative breast cancer, adjuvant therapy, endocrine therapy, invasive disease-free survival, PALLAS trial
- MeSH terms
- Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Piperazines, Prospective Studies, Pyridines, Time Factors, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
